Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Scientific Officer | July 28, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 34,000 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 51,000 · Balance 85,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 51,000 · Balance 34,000 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 51,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 85,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 85,000 RSUs reported in Table I (34,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 85,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 85,000 RSUs reported in Table I (34,000 RSUs) are subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2017 Filed Sep 29, 2017 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 900 | $70.00 | $63,000.00 |
DisclosureSEC source: 0000899243-17-022966 · doc4.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 900 | $6.41 | $5,769.00 |
DisclosureSEC source: 0000899243-17-022966 · doc4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 20:07 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $51.32 | $0.00 |
DisclosureSEC source: 0000899243-17-016222 · doc4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2027-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 9, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.